https://doi.org/10.4081/mem.2012.115
2
1
1
0
Smart Citations
2
1
1
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Valutazione etica in un processo di HTA di un trattamento per l'infertilità

Authors

Maria Luisa Di Pietro
mldipietro@rm.unicatt.it
Professore Associato di Medicina Legale e delle Assicurazioni, Istituto di Igiene, Italy.
Pietro Refolo
Dottore di ricerca in Bioetica, Istituto di Bioetica, Facoltà di Medicina e chirurgia "A. Gemelli", Università Cattolica del Sacro Cuore, Roma, Italy.
Come modalità di ricerca multidisciplinare, i programmi di Health Technology Assessment (HTA) hanno da sempre previsto, almeno in via teorica, la realizzazione anche delle valutazioni etiche sull'impiego di tecnologie sanitarie alla stregua di quelle sulla sicurezza, l'efficacia, l'impatto economico, l'impatto organizzativo, ecc. Nella pratica, tutto ciò è stato, però, per lo più disatteso e le valutazioni etiche hanno trovato posto nei report di HTA solo in tempi più recenti e con una frequenza comunque limitata. Con l'obiettivo di presentare il modus operandi e gli esiti di questo tipo di analisi ed eventualmente innescare un dibattito sull'argomento, il contributo riporta la valutazione delle conseguenze di tipo etico sull'uso di un trattamento per la cura della infertilità, il Fostimon. Più in particolare, tale valutazione ha fatto parte di un programma di HTA, organizzato dal Centro di Ricerca in Ingegneria sanitaria ambientale e valutazione delle tecnologie sanitarie dell'Università Cattolica del Sacro Cuore di Roma con lo scopo di stabilirne la preferibilità rispetto ad altri trattamenti.
----------
As multidisciplinary research, from a theoretical point of view, HTA programs should include the ethical assessment on the use of health technologies and also the assessment of safety, efficacy, economic impact, organizational impact, etc.. Nevertheless, in practice, the integration of the ethical dimension into HTA reports has been often limited. The paper includes the evaluation on the ethical consequences of the use of Fostimon, a treatment for infertility, with the aim of presenting modus operandi and results of this type of analysis and possibly opening the debate. Particularly, this assessment is part of an HTA program, organized by the Centro di Ricerca in Ingegneria sanitaria ambientale e valutazione delle tecnologie sanitarie of the Università Cattolica del Sacro Cuore of Rome with the purpose of determining the convenience of the treatment.

Dimensions

Altmetric

PlumX Metrics

Plum Print visual indicator of research metrics
    No metrics available.
see details

Downloads

Citations

Crossref
0
Scopus
0
Google Scholar
Europe PMC

How to Cite

Di Pietro, M. L., & Refolo, P. (2012). Valutazione etica in un processo di HTA di un trattamento per l’infertilità. Medicina E Morale, 61(6). https://doi.org/10.4081/mem.2012.115

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

An Open Access Publication is one that meets the following two conditions:

  1. the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.
  2. a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.